HC Wainwright Cuts Valneva (NASDAQ:VALN) Price Target to $17.00

Valneva (NASDAQ:VALN) had its target price trimmed by HC Wainwright from $18.00 to $17.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.17) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Stock Down 5.9 %

Valneva stock opened at $7.44 on Wednesday. The business has a fifty day moving average of $5.25 and a two-hundred day moving average of $5.68. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm has a market cap of $604.58 million, a P/E ratio of -57.23 and a beta of 1.98. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50.

Institutional Trading of Valneva

A number of hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares during the last quarter. AlphaCentric Advisors LLC lifted its holdings in shares of Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after purchasing an additional 29,748 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new stake in shares of Valneva during the 4th quarter valued at $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.